Successful early voriconazole treatment of Aspergillus infection in two non immunocompromised patients in Intensive Care Unit

Minerva Anestesiologica

Volumn 73, Issue 6, 2007, Pages 371-375

  Nataloni, Simonetta ^a   Gabbanelli, V ^a   Rossi, R ^a   Donati, A ^a   Pantanetti, S ^a   Pelaia, P ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Aspergillus; Bronchoalveolar lavage; Infections; Voriconazole

Indexed keywords

CEFOTAXIME; CEFTAZIDIME; DOBUTAMINE; GALACTOMANNAN; NORADRENALIN; PROPOFOL; SUFENTANIL; SULTAMICILLIN; VORICONAZOLE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; GASTROSCOPY; HEAD INJURY; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LABORATORY TEST; LUNG LAVAGE; MALE; PNEUMONIA; SIDE EFFECT; THORAX RADIOGRAPHY; VISUAL DISORDER;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; HUMANS; INTENSIVE CARE; MALE; MIDDLE AGED; PYRIMIDINES; TRIAZOLES;

EID: 34547522317     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Pittet D, Huguenin T, Dharan S, Sztajzel-Boissard J, Ducel G, Thorens JB et al. Unusual cause of lethal pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;154(2 Pt 1):541-4.
2. Kistemann T, Huneburg H, Exner M, Vacata V, Engelhart S. Role of increased environmental Aspergillus exposure for patients with chronic obstructive pulmonary disease (COPD) treated with corticosteroids in an intensive care unit. Int J Hyg Environ Health 2002;204:347-51.
3. Bulpa PA, Dive AM, Garrino MG, Delos MA, Gonzalez MR, Evrard PA et al. Chronic obstructive pulmonary disease patients with invasive pulmonary aspergillosis: benefits of intensive care? Intensive Care Med 2001;7:59-67.
4. Rello J, Esandi ME, Mariscal D, Gallego M, Domingo C, Valles J. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: report of eight cases and review. Clin Infect Dis 1998;26:1473-5.
5. Dimopoulos G, Piagnerelli M, Berre J, Eddafali B, Salmon I, Vincent JL. Disseminated aspergillosis in intensive care unit patients: an autopsy study. J Chemother 2003;15:71-5.
6. Vogeser M, Wanders A, Haas A, Ruckdeschel G. A four-year review of fatal Aspergillosis. Eur J Clin Microbiol Infect Dis 1999;18:42-5.
7. Pegues CF, Daar ES, Murthy AR. The epidemiology of invasive pulmonary aspergillosis at a large teaching hospital. Infect Control Hosp Epidemiol 2001;22:370-4.
8. Lentino JR, Rosenkranz MA, Michaels JA, Kurup VP, Rose HD, Rytel MW. Nosocomial aspergillosis: a retrospective review of airborne disease secondary to road construction and contaminated air conditioners. Am J Epidemiol 1982;116:430-7.
9. Denning DW, Munoz P. Advances in invasive fungal infection and antifungal therapy. Clin Microbiol Infect 2001;7:(Suppl 2):38-45.
10. Janssen JJ, Strack van Schijndel RJ, van der Poest Clement EH, Ossenkoppele GJ, Thijs LG et al. Outcome of ICU treatment in invasive aspergillosis. Intensive Care Med 1996;22:1315-22.
11. Manuel RJ, Kibbler CC. The epidemiology and prevention of invasive aspergillosis. J Hosp Infect 1998;39:95-109.
12. Machetti M, Feasi M, Mordini N, Van Lint MT, Bacigalupo A, Latge JP et al. Comparison of an enzyme immunoassay and a latex agglutination system for the diagnosis of invasive aspergillosis in bone marrow transplant recipients. Bone Marrow Transplant 1998;21:917-21.
13. Yu VL, Muder RR, Poorsattar A. Significance of isolation of Aspergillus from the respiratory tract in diagnosis of invasive pulmonary aspergillosis. Results from a three year prospective study. Am J Med 1986;81:249-54.
14. Andriole VT. Aspergillus infections: problems in diagnosis and treatment. Infect Agents Dis 1996;5:47-54.
15. Walsh TJ, Dixon DM. Nosocomial aspergillosis: environmental microbiology, hospital epidemiology, diagnosis and treatment. Eur J Epidem 1989;5:131-42.
16. Hodgson MJ, Morey P, Leung WY, Morrow L, Miller D, Javis BB et al. Bulding associated pulmonary disease from exposure to Stachybotrys chartarum and Aspergillus versicolor. Infect Control Hosp Epidemiol 1996;17:360-4.
17. Loo VG, Bertrand C, Dixon C, Vitye D, DeSalis B, McLean AO et al. Control of construction associated nosocomial aspergillosis in an antiquated hematology unit. J Occup Environ Med 1998;40:241-9.
18. Cannon JP, Garey KW, Danziger LH. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy 2001;21:1107-14.
19. Chiou CC, Groll AH, Walsh TJ. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. Oncologist 2000;5:120-35.
20. Graybill JR. The echinocandins, first novel class of antifungals in two decades:will they live up to their promise? Int J Clin Pract 2001;55:633-8.
21. Jeu LA, Piacenti FJ, Lyakhovetskiy AG, Fung HB. Voriconazole. Clin Ther 2003;25:1321-81.
22. Sutton DA, Sanche SE, Revankar SG, Fothergill AW, Rinaldi MG. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with head-tohead comparison to voriconazole. J Clin Microbiol 1999;37:2343-5.
23. Ghannoum MA, Kuhn DM. Voriconazole - better chances for patients with invasive mycoses. Eur J Med Res 2002;7:242-56.
24. Chandrasekar PH, Manavathu E. Voriconazole: a second-generation triazole. Drugs Today (Barc) 2001;37:135-48.
25. Van Epps HL, Feldmesser M, Pamer EG. Voriconazole inhibits fungal growth without impairing antigen presentation or T-cell activation. Antimicrob Agents Chemother 2003;47:1818-23.
26. de Lastours V, Lefort A, Zappa M, Dufour V, Belmatoug N, Fantin B. Two cases of cerebral aspergillosis successfully treated with voriconazole. Eur J Clin Microbiol Infect Dis 2003;22:297-9.
27. Marbello L, Nosari A, Carrafiello G, Anghilieri M, Cesana C, Cafro AM et al. Successful treatment with voriconazole of cerebral aspergillosis in an hematologic patient. Haematologica 2003;88:ECR05.
28. Muijsers RB, Goa KL, Scott LJ. Voriconazole: in the treatment of invasive aspergillosis. Drugs 2002;62:2655-66.
29. Chow L, Brown NE, Kunimoto D. An unusual case of pulmonary invasive aspergillosis and aspergilloma cured with voriconazole in a patient with cystic fibrosis Clin Infect Dis 2002;35:e106-10.
30. Lomaestro BM. Caspofungin. An echinocandin antifungal for the treatment of invasive aspergillosis. Formulary 2001;36:427-36.
31. Ullmann AJ. Rewiew of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr Med Res Opin 2003;19:263-71.
32. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36:630-7.
33. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563-71.
34. Herbrecht R, Denning DW, Patterson TF, Bennette JE, Greene RF, Oestmann JW et Al; for the Invasive Fungal Infection Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus Amphotericin B for prymary therapy. N Engl J Med 2002;347:408-15.
35. FDA Antiviral Drugs Advisory Committee, 2001. Briefing document for voriconazole. Pfizer. Online available at http://www.fda.gov/ohrms/ dockets/ac/01/briefing/3792b2_01_Pfizer.pdf